Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model

Renee R Handley1, Suzanne J Reid1, Rudiger Brauning2

  • 1Centre for Brain Research, School of Biological Sciences, The University of Auckland, Auckland 1010, New Zealand.

Insights

Huntington's disease (HD) involves abnormal urea metabolism, indicated by elevated urea levels in sheep models and human brains. This suggests urea cycle dysregulation may initiate HD neuropathogenesis.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin (HTT) gene.
  • The precise pathogenic mechanisms leading to neuronal dysfunction and death in HD remain incompletely understood.
  • Early molecular events in HD pathogenesis are crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To investigate early molecular changes in a prodromal model of Huntington's disease.
  • To identify biochemical alterations preceding significant neuropathology in HD.
  • To explore the role of urea metabolism in the initiation of HD neuropathogenesis.

Main Methods:

  • RNA-sequencing (RNA-seq) was performed on striatal tissue from a prodromal sheep model of HD (OVT73 line).
  • Levels of urea transporter SLC14A1 and the metabolite urea were quantified in sheep and human brain samples.
  • Analysis included comparison between HD cases and controls, including those with early-stage neuropathology.

Main Results:

  • Significantly increased levels of the urea transporter SLC14A1 and urea were observed in the striatum of the HD sheep model.
  • Elevated urea levels were confirmed in the striatum and cerebellum of HD sheep and in postmortem human brains from HD patients, including early-stage cases.
  • These findings suggest increased protein catabolism and potential urea cycle dysregulation in HD.

Conclusions:

  • Aberrant urea metabolism, evidenced by elevated urea levels, may represent a primary biochemical disruption in Huntington's disease.
  • Dysregulation of the urea cycle could be an initiating factor in HD neuropathogenesis.
  • These findings highlight urea metabolism as a potential therapeutic target for HD.